New inhaled therapy aims to slow lung scarring in progressive fibrosis
Disease control
Ongoing
This study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC